Adamas Pharmaceuticals Announces INROADS Phase 3 Trial Of ADS-5102 For Multiple Sclerosis Patients With Walking Impairment Achieved Primary Endpoint But Did Not Demonstrate Significant Effect On Secondary Walking Measures